FDA Fast Track Designation

US FDA Grants Fast Track Designation for Pacritinib Treatment in VEXAS Syndrome

WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration

Topics